Bengaluru-based biotech startup Zumutor Biologics has raised $7.3 million in a Pre-Series B funding round. The company received support from its existing investors, Accel and Bharat Innovation Fund. Along with them, new investors also joined the round. These include Premji Invest, well-known investor Ashish Kacholia, and Raj Dandu Family Office.
This fresh investment marks an important step for the startup as it moves deeper into clinical research and works toward building new cancer treatments for patients around the world. The company plans to use the capital for major research programs, expansion of trials, and global development of its lead cancer drug candidate.
The funding round shows strong confidence from both old and new investors. It also highlights growing interest in Indian biotech startups that are building advanced healthcare solutions with global potential.
Focus on Completing Important Clinical Trials
Zumutor plans to use a large part of the new funding to complete the ongoing US FDA Phase 1 clinical trial of its lead drug candidate called ZM008.
Clinical trials are a critical stage in drug development. In Phase 1 trials, companies test whether a new treatment is safe for human use. This phase helps researchers understand how the drug works inside the body and whether patients can tolerate it safely.
The company also plans to support Phase 1B expansion cohorts. This stage allows researchers to test the drug on more patients after early safety checks show positive results.
Apart from this, Zumutor wants to begin global Phase 2 studies. These studies will happen in multiple countries, including India. Phase 2 trials help researchers study how well the treatment works for patients while continuing to monitor safety.
This step shows that Zumutor now wants to move faster in its clinical development journey.
Startup Works on Advanced Cancer Treatment
Zumutor Biologics was founded by entrepreneur Kavitha Iyer Rodrigues. The company focuses on immuno-oncology, a field of medicine that uses the human immune system to fight cancer.
Unlike traditional cancer treatment methods that directly attack cancer cells, immuno-oncology helps the body defend itself naturally. Scientists believe this approach may offer better long-term treatment options for many cancer patients.
The company has spent years building therapies that focus on the body’s natural defense system. Its main goal is to create better cancer treatments that can help patients with difficult forms of cancer.
This area of healthcare research has become one of the fastest-growing sectors in the global biotech industry.
ZM008 Becomes the Company’s Most Important Program
Zumutor’s lead program is ZM008, which has become the center of the company’s research efforts.
The company describes ZM008 as a first-in-class NK cell checkpoint therapy. NK stands for natural killer cells. These are special immune cells inside the human body that help detect and destroy harmful cells, including cancer cells.
Cancer often develops ways to escape attacks from the immune system. This makes treatment very difficult, especially in advanced stages.
ZM008 aims to remove those barriers and help natural killer cells recognize and destroy cancer cells more effectively.
The company believes this treatment can create a stronger immune response and improve outcomes for patients with serious cancer conditions.
Because this approach works differently from many existing treatments, researchers consider it an exciting development in modern cancer therapy.
Early Clinical Results Show Positive Signs
Zumutor has shared that early clinical data from the ongoing Phase 1 studies has shown encouraging results.
According to the company, researchers have seen promising early clinical signals in selected hard-to-treat tumor types. These are cancers that usually do not respond easily to existing treatments and often create major challenges for doctors.
Positive early results have helped strengthen confidence in the company’s immunotherapy platform.
Early clinical success is an important milestone for biotech startups because it helps prove that years of scientific research may lead to successful treatment development.
It also helps attract investor trust and opens doors for larger future funding rounds.
For Zumutor, these results have created strong momentum as the company moves ahead with bigger clinical programs.
Company Plans Broader Cancer Studies
Apart from ongoing clinical work, Zumutor plans to use the funding for combination studies of ZM008 across multiple cancer indications.
Combination studies allow researchers to test a new drug alongside other treatments. Sometimes, a drug works better when doctors use it with existing therapies instead of using it alone.
The company wants to study how ZM008 performs across different cancer types and treatment combinations.
This broader research strategy may help Zumutor identify more treatment opportunities and expand the possible use of its drug candidate.
By studying multiple cancer indications, the company hopes to create wider medical applications for its immunotherapy platform.
This move could strengthen its long-term position in the highly competitive biotech sector.
Indian Startup Builds Global Presence
Zumutor Biologics operates from Bengaluru but has built operations in both India and the United States.
This international presence helps the company conduct research across global markets and work closely with international healthcare regulators.
The company now joins a growing group of Indian biotech startups that are developing advanced cancer treatments for global patients.
India’s biotech sector has seen strong growth in recent years as more startups focus on research-led healthcare innovation instead of traditional pharmaceutical manufacturing.
Companies like Zumutor show that Indian startups now have the ability to create world-class medical solutions that can compete internationally.
This also reflects how global investors are paying close attention to Indian healthcare innovation.
A Big Step Toward Future Cancer Treatment
The $7.3 million funding round marks an important moment for Zumutor Biologics.
The company now has fresh capital to push forward with clinical development, global expansion, and deeper research around its lead therapy ZM008.
Support from investors like Accel, Bharat Innovation Fund, Premji Invest, Ashish Kacholia, and Raj Dandu Family Office shows strong belief in the company’s long-term vision.
Cancer treatment remains one of the biggest challenges in modern healthcare. Startups like Zumutor are working to create smarter and more advanced therapies that may improve treatment options for patients worldwide.
As the company moves toward Phase 2 global trials and expands its research program, Zumutor now stands at an important stage in its journey.
Its progress may help shape the future of cancer treatment, not only in India but across global healthcare markets.
Also Read – Countries With the Highest Number of Startups in 2026